{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:14:40Z","timestamp":1772558080801,"version":"3.50.1"},"reference-count":60,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jbspin.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,5,29]],"date-time":"2016-05-29T00:01:02Z","timestamp":1464480062000},"page":"21-27","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Herpes zoster: Risk and prevention during immunomodulating therapy"],"prefix":"10.1016","volume":"84","author":[{"given":"Cong Tri","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Ducancelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Masson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Lunel-Fabiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2016.04.001_bib0305","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jpain.2007.10.002","article-title":"Natural history and treatment of herpes zoster","volume":"9","author":"Schmader","year":"2008","journal-title":"J Pain"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0310","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1086\/651199","article-title":"Influence of age and nature of primary infection on varicella-zoster virus\u2014specific cell-mediated immune responses","volume":"201","author":"Weinberg","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0315","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0320","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jbspin.2014.01.015","article-title":"Systemic diseases and biotherapies: understanding, evaluating, and preventing the risk of hepatitis B reactivation","volume":"81","author":"Lunel-Fabiani","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jbspin.2015.08.008","article-title":"Vaccinations in adults with chronic inflammatory joint disease: Immunization schedule and recommendations for patients taking synthetic or biological disease-modifying antirheumatic drugs","volume":"83","author":"Morel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0330","article-title":"Influenza vaccination status in rheumatoid arthritis and spondyloarthritis patients receiving biologic DMARDs","author":"Michel","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0335","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1002\/acr.22628","article-title":"Herpes zoster reactivation in patients with rheumatoid arthritis: Analysis of disease characteristics and disease modifying anti-rheumatic drugs","volume":"67","author":"Pappas","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0340","article-title":"Herpes zoster infection risk in auto-immune and inflammatory diseases: implications for vaccination","volume":"66","author":"Yun","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0345","first-page":"77","article-title":"Vaccinating HIV patients: focus on human papillomavirus and herpes zoster vaccines","volume":"15","author":"Koenig","year":"2013","journal-title":"AIDS Rev"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0350","doi-asserted-by":"crossref","first-page":"g2911","DOI":"10.1136\/bmj.g2911","article-title":"Quantification of risk factors for herpes zoster: population based case-control study","volume":"348","author":"Forbes","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0355","doi-asserted-by":"crossref","first-page":"e1001420","DOI":"10.1371\/journal.pmed.1001420","article-title":"Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study","volume":"10","author":"Langan","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0360","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jbspin.2014.10.012","article-title":"Overview of biologic treatments in the elderly","volume":"82","author":"Lahaye","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0365","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0370","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0375","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti\u2013tumor necrosis factor therapy and the risk of herpes zoster","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0380","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/acr.22470","article-title":"Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy: herpes zoster in RA patients taking biologic agents","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0385","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0390","first-page":"962","article-title":"Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review","volume":"30","author":"Zhang","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0395","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-\u03b1 agents","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0400","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0405","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jbspin.2013.07.009","article-title":"Risk of herpes\/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis","volume":"81","author":"Che","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0410","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1086\/598331","article-title":"Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis","volume":"48","author":"McDonald","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0415","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1756-185X.2012.01715.x","article-title":"Lack of adverse effect of anti-tumor necrosis factor-\u03b1 biologics in treatment of rheumatoid arthritis: 5years follow-up","volume":"15","author":"Dewedar","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0420","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0425","article-title":"Herpes zoster and tofacitinib: the risk of concomitant nonbiologic therapy","volume":"67","author":"Winthrop","year":"2015","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0430","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/jid.2011.383","article-title":"Risk of herpes zoster in patients receiving anti-TNF-\u03b1 in the prospective French RATIO registry","volume":"132","author":"Serac","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0435","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/jdv.12307","article-title":"The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions","volume":"28","author":"Adelzadeh","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0440","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1136\/ard.2009.125658","article-title":"Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists","volume":"69","author":"Garcia-Doval","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0445","article-title":"Complications of varicella zona virus infections are more frequent in patients treated with biologic drugs when combined with steroids","volume":"66","author":"Morel","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0450","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/art.39399","article-title":"Comparative risk of hospitalized infection associated with biologic agents in rheumatoid arthritis patients enrolled in Medicare","volume":"68","author":"Yun","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0455","first-page":"1","article-title":"Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"57","author":"Harpaz","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0460","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jbspin.2013.09.001","article-title":"Recommendations for using TNF\u03b1 antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health","volume":"80","author":"Go\u00ebb","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0465","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa051016","article-title":"A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults","volume":"352","author":"Oxman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0470","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1093\/cid\/ciu918","article-title":"Long-term persistence of zoster vaccine efficacy","volume":"60","author":"Morrison","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0475","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.vaccine.2014.10.039","article-title":"Modeling the durability of ZOSTAVAX\u00ae vaccine efficacy in people \u226560years of age","volume":"33","author":"Li","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0480","article-title":"Long term effectiveness of herpes zoster vaccine among patients with autoimmune and inflammatory diseases","volume":"67","author":"Yun","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0485","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/CDLI.8.5.871-879.2001","article-title":"Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus","volume":"8","author":"Smith","year":"2001","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0490","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/S0264-410X(99)00552-6","article-title":"Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55years of age and older","volume":"18","author":"Levine","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0495","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.vaccine.2011.11.096","article-title":"Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults \u226560years of age","volume":"30","author":"Vermeulen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0500","first-page":"67","article-title":"Safety, clinical and immunologic effectiveness of the live zoster vaccine administered to patients receiving anti-TNF biologics","author":"Curtis","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0505","article-title":"Assessment of immunogenicity of live zoster vaccination (Zostavax\u00ae) in rheumatoid arthritis patients on background methotrexate before and after initiating tofacitinib or placebo","volume":"67","author":"Winthrop","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0510","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/ciu498","article-title":"Vaccination against zoster remains effective in older adults who later undergo chemotherapy","volume":"59","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0515","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jama.2012.7304","article-title":"Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases","volume":"308","author":"Zhang","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0520","doi-asserted-by":"crossref","first-page":"545","DOI":"10.7326\/0003-4819-152-9-201005040-00004","article-title":"Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial","volume":"152","author":"Simberkoff","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0525","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/cid\/cir970","article-title":"Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years","volume":"54","author":"Schmader","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0530","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1093\/cid\/ciu058","article-title":"Herpes zoster caused by vaccine-strain varicella zoster virus in an immunocompetent recipient of zoster vaccine","volume":"58","author":"Tseng","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0535","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0540","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/ajh.22196","article-title":"Experience with use of Zostavax\u00ae in patients with hematologic malignancy and hematopoietic cell transplant recipients","volume":"87","author":"Naidus","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0545","article-title":"Safety of zoster vaccination administration in rheumatic patients on current biologic therapy","volume":"66","author":"Lindsey","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0550","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1086\/522129","article-title":"Strategies for herpes zoster vaccination of immunocompromised patients","volume":"197","author":"Cohen","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0555","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa013441","article-title":"Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants","volume":"347","author":"Hata","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0560","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/infdis\/jit344","article-title":"Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults","volume":"208","author":"Mullane","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0565","article-title":"Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with autoimmune disease","volume":"65","author":"McAdam","year":"2013","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0570","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550years of age","volume":"208","author":"Chlibek","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0575","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.4161\/hv.24269","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ\/su): A phase-I, open-label study in Japanese adults","volume":"9","author":"Lal","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0580","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0585","article-title":"Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults","author":"Chlibek","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0590","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1182\/blood-2014-04-573048","article-title":"A phase 1\/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients","volume":"124","author":"Stadtmauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0595","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu606","article-title":"Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1\/2a randomized, placebo-controlled study","author":"Berkowitz","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2016.04.001_bib0600","article-title":"Herpes zoster and the short term risk for ischemic stroke in patients with autoimmune diseases","volume":"67","author":"Calabrese","year":"2015","journal-title":"Arthritis Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16300525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X16300525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T11:58:03Z","timestamp":1536667083000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X16300525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1297319X16300525"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.04.001","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes zoster: Risk and prevention during immunomodulating therapy","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}